首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Clinical Lung Cancer

Clinical Lung Cancer杂志,由Elsevier出版,于1999年创刊,Bimonthly,出版语言English,ISSN:1525-7304,E-ISSN:1938-0690。

投稿咨询
Clinical Lung Cancer
Clinical Lung Cancer
Clinical Lung Cancer
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
3区
影响因子
3.9
CiteScore
6.2
期刊收录
SCI、SCIE

Clinical Lung Cancer(中文译名:《临床肺癌》),ISSN:1525-7304,EISSN:1938-0690,是Elsevier出版的国际性学术期刊,创刊于1999年,以Bimonthly形式稳定发行,2026年总发文量约157篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达3.9,2025年期刊CiteScore为6.2,2025年期刊自引率约2.6%,在中科院期刊分区体系中位列医学大类3区,在所属学科领域具备高学术影响力与国际认可度。Clinical Lung Cancer长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期较慢,6-12周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、Japan、Italy、France、Canada、Spain等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMUNIVERSITY OF CALIFORNIA SYSTEM、UNIVERSITY OF PENNSYLVANIA、INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)、UNICANCER、MAYO CLINIC、UNIVERSITY OF COLORADO SYSTEM等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
3区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
3区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
4区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 120 / 333

64.1

学科:ONCOLOGY SCIE Q2 129 / 333

61.41

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 123 / 328

62.7

学科:ONCOLOGY SCIE Q2 125 / 328

62.04


中国学者近期发文

1
Efficacy and Safety of Firmonertinib Plus Anlotinib as First-Line Treatment for Advanced NSCLC With EGFR Mutations: A Single-Arm, Phase I/II Tria

Author:Shi, Huiyang; Zhu, Haohua; Tang, Le; Lu, Jingyu; Zhu, Kai; Wang, Miaohan; Hu, Xingsheng; Shi, Yuankai

Journal: CLINICAL LUNG CANCER. 2026; Vol. 27, Issue 3, pp. 170-179. DOI: 10.1016/j.clc.2025.11.010

2
Thoracic Radiotherapy and Radiation Time Would Affect the Efficacy of Advanced Non-Small Cell Lung Cancer for Patients Who Responded to TKIs Treatmen

Author:Ma, Jinbo; Li, Cheng; Wang, Xiao; Zhang, Pengfei; Ma, Xiaoyan; Kan, Hongxing; Zhang, Wei

Journal: CLINICAL LUNG CANCER. 2026; Vol. 27, Issue 2, pp. 126-134. DOI: 10.1016/j.clc.2025.12.009

3
TIGOS Trial: A Randomized, Double-Blind , Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cance

Author:Paz-Ares, Luis G.; O'Byrne, Kenneth John; Johnson, Melissa L.; Reck, Martin; Girard, Nicolas; Hayashi, Hidetoshi; Zhou, Caicun; Gharpure, Vishwanath Suresh; Pisupati, Radhika; Pacius, Misena; Ready, Neal E

Journal: CLINICAL LUNG CANCER. 2026; Vol. 27, Issue 2, pp. 140-145. DOI: 10.1016/j.clc.2026.01.009

4
Effect of adjuvant EGFR-TKI therapy on the prognosis of pathological stage I invasive lung adenocarcinoma with sensitive EGFR mutation

Author:Liu, Zetao; Peng, Zhiyu; Cao, Jie; Huang, Zhaokang; Liao, Xizhou; Zong, Xiaorong; Guo, Chenglin; Mei, Jiandong

Journal: CLINICAL LUNG CANCER. 2026; Vol. 27, Issue 2, pp. 177-188. DOI: 10.1016/j.clc.2025.09.001

5
Anaplastic Lymphoma Kinase Rearrangement and Tumor Spread Through Air Spaces Is Associated with Worse Clinical Outcomes for Resected Stage IA Lung Adenocarcinom

Author:Shi, Jinghan; Xu, Kuan; Liu, Xufeng; Shi, Minjun; Ji, Chunyu; Ye, Bo

Journal: CLINICAL LUNG CANCER. 2026; Vol. 27, Issue 2, pp. 151-160. DOI: 10.1016/j.clc.2025.08.016

6
Management of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC): An Updated Revie

Author:Yeung, Anson Man Lok; Chung, James; Chow, Hang

Journal: CLINICAL LUNG CANCER. 2026; Vol. 87, Issue 2, pp. 85-97. DOI: 10.1016/j.clc.2026.01.003

7
Cumulative Incidence and Type-Specific Risk Factors of Pneumonitis After Definitive Chemoradiotherapy With or Without Immunotherapy in Locally Advanced Non-Small Cell Lung Cance

Author:Sun, Jiawen; Dong, Xin; Fu, Zhixue; Han, Sen; Liu, Yuliang; Shi, Anhui; Yu, Huiming; Zhao, Yuting; Deng, Wei; Jiang, Leilei; Yang, Dan; Chang, Xiao; Long, Liuhua; Yu, Jiayi; Teng, Yue; Yu, Rong; Wang, Weihu

Journal: CLINICAL LUNG CANCER. 2026; Vol. 27, Issue 2, pp. 14-24. DOI: 10.1016/j.clc.2025.11.020

8
Predicting Severe Radiation Pneumonitis in Patients With Locally-Advanced Non-Small-Cell Lung Cancer After Thoracic Radiotherapy: Development and Validation of a Nomogram Based on the Clinical, Hematological, and Dose-Volume Histogram Parameter

Author:Zhang, Ying; Zhou, Shi-Hong; Yan, Yu-Jie; Wu, Lei-Lei; Yuan, Xiao-Shuai; Hu, Min; Kang, Jing-Jing; Jiang, Chen-Xue; Zhu, Yao-Yao; Yang, Shuang-Yan; Zhao, Rui-Feng; Hu, Jian; Hu, Min-Ren; Liu, Hui; Liu, Liang; Zhao, Lan; Xu, Ya-Ping

Journal: CLINICAL LUNG CANCER. 2025; Vol. 26, Issue 5, pp. 393-406. DOI: 10.1016/j.clc.2025.02.009

9
Prognostic Implications of Lymph Node Status in Non-Small-Cell Lung Cancer Patients Before and After Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective Stud

Author:Ma, Ran; Yang, Haitang; Ge, Yong; Ma, Tianyue; Wang, Jiayi; Li, Shuyuan; Feng, Tianci; Feng, Shoujie; Zhang, Cheng; Sun, Teng; Yao, Feng; Yi, Jun; Zhang, Hao; Song, Pingping

Journal: CLINICAL LUNG CANCER. 2025; Vol. 26, Issue 5, pp. 370-383. DOI: 10.1016/j.clc.2025.04.004

10
Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cance

Author:Zhu, Zihao; Wu, Jianfeng; Zhao, Lijun; Jiang, Ning; Chen, Yu; Song, Xue; Li, Ming; Jiang, Ming; Shi, Meiqi; Yu, Shaorong; Ren, Binhui; Yin, Rong; Jiang, Feng; Wang, Li; Kong, Cheng; Zhu, Xiangzhi

Journal: CLINICAL LUNG CANCER. 2025; Vol. 26, Issue 4, pp. -. DOI: 10.1016/j.clc.2025.01.012


在线咨询

Clinical Lung Cancer

国际简称:CLIN LUNG CANCER参考译名:临床肺癌

年发文量:157 CiteScore:6.2 是否预警:否 Gold OA文章占比:12.17% 研究类文章占比:91.08%

杂志社联系方式:CIG MEDIA GROUP, LP, 3500 MAPLE AVENUE, STE 750, DALLAS, USA, TX, 75219-3931

Clinical Lung Cancer